Replies to post #15806 on Momenta Pharmaceuticals, Inc. (MNTA)

[jmkobers]

I don't doubt Dew's contention that NVS/MNTA strongly suggested they will launch at risk. Or perhaps they meant they strongly suspected they wouldn't have to, as Dew's previous message implies.

Perhaps it is you who could be mistaken? Wait no that could never be, you are always right.

PS - I am going to go with 1 on the cookie query but math has never been my strong suit

[DewDiligence]

The 40mg-Copaxone patent case in US District Court (scheduled for 9/26/16) is separate from the IPR at the US PTO. Only the Court can issue an injunction against NVS/MNTA’s launch, so it’s the Court’s ruling that matters vis-à-vis an at-risk launch.

In #msg-124628031, I pointed out this distinction in the first sentence.